Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00098683 · ClinicalTrials.gov registry record · Phase 2
Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes
A Phase 2 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT00098683 is a Phase 2 study that has completed, run by Children's Oncology Group. The registered enrollment target is 10 participants.
The verdict
NCT00098683, a Phase 2 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as amifostine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well amifostine works in treating young patients with newly diagnosed de novo myelodysplastic syndromes.
Interventions
- DRUG amifostine trihydrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2005-01 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00098683
The ClinicalTrials.gov registry entry for NCT00098683 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which amifostine trihydrate is the first listed.
NCT00098683 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00098683 about?
NCT00098683 is a clinical study titled "Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes". RATIONALE: Drugs used in chemotherapy, such as amifostine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well amifostine works in treating young patients with newly diagnosed de ...
What is the current status of trial NCT00098683?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2005-01. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00098683?
The interventions under investigation include: amifostine trihydrate (DRUG).
Who is sponsoring clinical trial NCT00098683?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.